Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.81% |
| 2 | Technology | 15.51% |
| 3 | Consumer Discretionary | 11.84% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3651
Rallybio
RLYB
$84.7M
| $91K | ﹤0.01% |
+1,725
| New | +$102K |
|
|
ATIP
3652
DELISTED
ATI Physical Therapy, Inc.
ATIP
| $91K | ﹤0.01% |
5,952
+874
| +17% | +$29.5K |
|
3653
Oriental Culture Holding
OCG
$3.28M
| $90K | ﹤0.01% |
54
-21
| -28% | -$44.9K |
|
3654
Capricor Therapeutics
CAPR
$241M
| $89K | ﹤0.01% |
23,021
+12,821
| +126% | +$61.2K |
|
3655
ReTo Eco-Solutions
RETO
$24.6M
| $89K | ﹤0.01% |
1
| – | – |
|
|
AUTL
3656
Autolus Therapeutics
AUTL
$519M
| $88K | ﹤0.01% |
46,300
+21,100
| +84% | +$53.4K |
|
3657
AEye
LIDR
$58.4M
| $88K | ﹤0.01% |
+6,130
| New | +$159K |
|
3658
Comstock
LODE
$241M
| $88K | ﹤0.01% |
32,021
+27,506
| +609% | +$100K |
|
|
SUPV
3659
Grupo Supervielle
SUPV
$792M
| $88K | ﹤0.01% |
+40,900
| New | +$75K |
|
|
EPIX
3660
DELISTED
ESSA Pharma
EPIX
| $87K | ﹤0.01% |
34,624
-151,286
| -81% | -$434K |
|
3661
Moleculin Biotech
MBRX
$2.89M
| $87K | ﹤0.01% |
219
-6
| -3% | -$2.53K |
|
|
RBOT
3662
DELISTED
Vicarious Surgical
RBOT
| $87K | ﹤0.01% |
+1,433
| New | +$133K |
|
|
VIOT
3663
Viomi Technology
VIOT
$51.8M
| $87K | ﹤0.01% |
81,264
-4,100
| -5% | -$3.93K |
|
|
WKEY
3664
WISeKey
WKEY
$78.2M
| $87K | ﹤0.01% |
19,620
-720
| -4% | -$2.93K |
|
|
MAAS
3665
Maase Inc
MAAS
$8.63B
| $87K | ﹤0.01% |
190
-69
| -27% | -$29.3K |
|
|
OKUR
3666
OnKure Therapeutics
OKUR
$166M
| $87K | ﹤0.01% |
3,720
-580
| -13% | -$15.4K |
|
|
RVPH
3667
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $86K | ﹤0.01% |
+1,015
| New | +$77.4K |
|
3668
Stagwell
STGW
$2.2B
| $86K | ﹤0.01% |
13,900
-61,400
| -82% | -$443K |
|
|
BIOC
3669
DELISTED
Biocept, Inc.
BIOC
| $86K | ﹤0.01% |
5,410
-203
| -4% | -$4.48K |
|
3670
NanoViricides
NNVC
$38.8M
| $85K | ﹤0.01% |
76,973
+5,907
| +8% | +$9.21K |
|
|
TMQ
3671
Trilogy Metals
TMQ
$594M
| $85K | ﹤0.01% |
154,758
-81,263
| -34% | -$47.4K |
|
|
SNCE
3672
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $85K | ﹤0.01% |
10,267
+5,252
| +105% | +$103K |
|
3673
EyePoint Inc
EYPT
$978M
| $84K | ﹤0.01% |
+24,000
| New | +$106K |
|
3674
Soluna Holdings
SLNH
$191M
| $84K | ﹤0.01% |
12,823
+6,667
| +108% | +$164K |
|
|
RNLX
3675
DELISTED
Renalytix plc American Depositary Shares
RNLX
| $84K | ﹤0.01% |
45,000
-81,002
| -64% | -$127K |
|
Similar funds
Renaissance Technologies's Q4 2022 Portfolio in Review
As of Q4 2022, Renaissance Technologies held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Renaissance Technologies added most to Apple in Q4 2022, an estimated $839M increase.
- Renaissance Technologies's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Renaissance Technologies fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Renaissance Technologies's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Renaissance Technologies opened 626 new positions and closed 524 in Q4 2022.
- Renaissance Technologies's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.